… This work was supported by Novartis Pharma AG and in part by Grant GM 24211 from the
National Institutes of Health. The liquid chromatograph/tandem mass spectrometer was …

… Defined as a C3 level of <0.9 gm/liter or a C4 level of <180 mg/liter. ¶ Defined according
to the rules of the central laboratory, which may have varied across treatment regions. …

<p>The neurite outgrowth inhibitor, Nogo-A, has been shown to be overexpressed in
skeletal muscle in amyotrophic lateral sclerosis (ALS); it is both a potential biomarker and …

In this manuscript, we have presented the development of a novel platform physiologically-based
pharmacokinetic (PBPK) model to characterize brain disposition of mAbs in the mouse, …

Everolimus is a novel macrolide immunosuppressant developed for the prophylaxis of
allogeneic renal or cardiac transplant rejection. Treatments with immunosuppressants are often …

This study sought to determine effects of multiple dosing of prasterone (DHEA,
dehydroepiandrosterone) on the pharmacokinetics of prednisolone and endogenous cortisol …

The interaction between dehydroepiandrosterone (DHEA) and prednisolone (PD) in the
inhibition of rat lymphocyte proliferation was evaluated. The in vitro proliferative response of …

The effects of multiple-dosing with dehydroepiandrosterone sulfate (DHEA-SO4) on the
pharmacokinetics and pharmacodynamics of prednisolone were examined. Prednisolone (25 mg…

Prednisolone (5 mg/kg intravenous) was administered to adrenalectomized male and
female Sprague‐Dawley rats (250–350 g) to assess the effects of gender on disposition and …

… Meno-Tetang … Meno-Tetang … Meno-Tetang …